{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:34:27Z","timestamp":1794407667107,"version":"4.9.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapsed or refractory (r\/r) mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a poor prognosis. Bruton tyrosine kinase (BTK) is a mediator of B-cell receptor signaling and is associated with the development of B-cell lymphomas. Patients with r\/r MCL were enrolled in this phase 1\/2 study and treated with orelabrutinib, a novel, highly selective BTK inhibitor. The median number of prior regimens was 2 (range, 1-4). The median age was 62 years (range, 37-73 years). Eligible patients received oral orelabrutinib 150\u00a0mg once daily (n\u00a0= 86) or 100\u00a0mg twice daily (n\u00a0= 20) until disease progression or unacceptable toxicity. A dose of 150\u00a0mg once daily was chosen as the preferred recommended phase 2 dose. After a median follow-up duration of 23.8\u00a0months, the overall response rate was 81.1%, with 27.4% achieving a complete response and 53.8% achieving a partial response. The median duration of response and progression-free survival were 22.9 and 22.0\u00a0months, respectively. The median overall survival (OS) was not reached, and the rate of OS at 24\u00a0months was 74.3%. Adverse events (AEs) occurring in &amp;gt;20% of patients were thrombocytopenia (34.0%), upper respiratory tract infection (27.4%), and neutropenia (24.5%). Grade \u22653 AEs were infrequent and most commonly included thrombocytopenia (13.2%), neutropenia (8.5%), and anemia (7.5%). Three patients discontinued treatment because of treatment-related adverse events (TRAEs), but no fatal TRAEs were reported. Orelabrutinib showed substantial efficacy and was well tolerated in patients with r\/r MCL. This trial was registered at www.clinicaltrials.gov as #NCT03494179.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009168","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T08:50:10Z","timestamp":1681980610000},"page":"4349-4357","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study"],"prefix":"10.1182","volume":"7","author":[{"given":"Li-Juan","family":"Deng","sequence":"first","affiliation":[{"name":"1Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Shu","family":"Zhou","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Zhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Li","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yan","family":"Ji","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Qilu Hospital, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"8Department of Hematology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[{"name":"9Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Shandong Provincial Hospital, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jun","family":"Gao","sequence":"additional","affiliation":[{"name":"11Department of Hematology, The First Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Lai","family":"Zhang","sequence":"additional","affiliation":[{"name":"12Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"13Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"14Department of Lymphoma, The First Affiliated Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"15Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"16Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ning","family":"Cao","sequence":"additional","affiliation":[{"name":"17Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zun-Min","family":"Zhu","sequence":"additional","affiliation":[{"name":"18Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Da","family":"Hu","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Jing","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yang","family":"Ding","sequence":"additional","affiliation":[{"name":"22Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"23InnoCare Pharma Limited, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Bin","family":"Zhao","sequence":"additional","affiliation":[{"name":"23InnoCare Pharma Limited, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"23InnoCare Pharma Limited, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Min","family":"Tian","sequence":"additional","affiliation":[{"name":"23InnoCare Pharma Limited, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ping","family":"Song","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qin","family":"Song","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"6","key":"2023082114343772100_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2023082114343772100_bib2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"11","key":"2023082114343772100_bib3","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023082114343772100_bib4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","author":"Eyre","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023082114343772100_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2023082114343772100_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"3-4","key":"2023082114343772100_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1155\/2001\/28962","article-title":"Role of Bruton's tyrosine kinase in B cell development","volume":"8","author":"Maas","year":"2001","journal-title":"Dev Immunol"},{"key":"2023082114343772100_bib8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","article-title":"The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective","volume":"175","author":"Satterthwaite","year":"2000","journal-title":"Immunol Rev"},{"issue":"5250","key":"2023082114343772100_bib9","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"2023082114343772100_bib10","author":"IMBRUVICA\u00ae (ibrutinib)","year":"2020"},{"issue":"6","key":"2023082114343772100_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10121","key":"2023082114343772100_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"2023082114343772100_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-021-01174-3","article-title":"Zanubrutinib monotherapy in relapsed\/refractory mantle cell lymphoma: a pooled analysis of two clinical trials","volume":"14","author":"Zhou","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"2023082114343772100_bib14","author":"CALQUENCE\u00ae (acalabrutinib) 100\u00a0mg capsules","year":"2019"},{"key":"2023082114343772100_bib15","author":"BRUKINSA\u00ae (zanubrutinib) 80\u00a0mg capsules","year":"2021"},{"issue":"suppl 16","key":"2023082114343772100_bib16","first-page":"CT132","article-title":"Orelabrutinib, a potent and selective Bruton\u2019s tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties [abstract]","volume":"80","author":"Zhang","year":"2020","journal-title":"In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 27-28 April 2020 and 22-24 June 2020; Philadelphia, PA. Cancer Res"},{"key":"2023082114343772100_bib17","doi-asserted-by":"crossref","first-page":"101682","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2023082114343772100_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in\u00a0vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"27","key":"2023082114343772100_bib19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"2023082114343772100_bib20","unstructured":"Cancer Therapy Evaluation Program\n          . CTCAE, version 4.03. Accessed 14 April 2022. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_30."},{"issue":"6","key":"2023082114343772100_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2023082114343772100_bib22","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2023082114343772100_bib23","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2023082114343772100_bib24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s002590050275","article-title":"Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography","volume":"25","author":"Stumpe","year":"1998","journal-title":"Eur J Nucl Med"},{"issue":"10","key":"2023082114343772100_bib25","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2007-06-097238","article-title":"The role of FDG-PET scans in patients with lymphoma","volume":"110","author":"Seam","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2023082114343772100_bib26","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"2023082114343772100_bib27","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2005.01.891","article-title":"Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography","volume":"23","author":"Juweid","year":"2005","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4349\/2072731\/blooda_adv-2022-009168-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4349\/2072731\/blooda_adv-2022-009168-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T10:35:38Z","timestamp":1692614138000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4349\/495388\/Orelabrutinib-for-the-treatment-of-relapsed-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009168","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}